Sen-Jam Pharmaceutical
Own a stake for health equality; affordable and accessible for all
Overview
Platform
Dealmaker Securities
Start Date
04/25/2023
Close Date
04/25/2024
Min. Goal
$10,000,000
Max. Goal
$10,000,000
Min. Investment
$0
Security Type
Convertible Note
Series
Series A
SEC Filing Type
RegD 506(c)
Year Founded
2017
Industry
Healthcare & Pharmaceuticals
Tech Sector
Biotech
Location
Huntington, New York
Sen-Jam Pharmaceutical, with a valuation of $70 million, is raising funds on Dealmaker Securities with a Reg D 506(c) raise. The pharmaceutical company makes highly accessible, safe, and affordable drugs that work. The drugs of Sen-Jam Pharmaceutical combine NSAIDs and antihistamines to prevent inflammation and associated pain. Sen-Jam Pharmaceutical is majorly targeting opioid withdrawal, alcohol hangover prevention, and COVID-19 therapeutic. The company has a strong global IP portfolio with 40 patents and world-class partners. Jim Iversen and Jackie Iversen founded Sen-Jam Pharmaceutical in August 2017. The current crowdfunding campaign has a minimum target of $10,000 and a maximum target of $10 million. The campaign proceeds will be used to advance the different phases of its clinical trials.
Create a free account today to gain access to KingsCrowd analytics.
Raise History
| Offering Name | Close Date | Platform | Valuation/Cap | Total Raised | Security Type | Status | Reg Type |
|---|---|---|---|---|---|---|---|
| Sen-Jam Pharmaceutical | 04/29/2024 | Wefunder | $80,000,000 | $0 | SAFE | Active | RegCF |
| Sen-Jam Pharmaceutical | 04/25/2024 | Dealmaker Securities | - | $0 | Convertible Note | Active | RegD 506(c) |
| Sen-Jam Pharmaceutical | 01/11/2023 | StartEngine | $69,979,019 | $312,093 | Equity - Common | Funded | RegCF |
| Sen-Jam Pharmaceutical | 07/31/2022 | Wefunder | $25,000,000 | $1,008,951 | Convertible Note | Funded | RegCF |
Create a free account today to gain access to KingsCrowd analytics.
Upgrade to gain access
Pay Monthly
Annually (Save 17%)
-
$12.42 /month
billed annually - Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings (excluding risk)
- Advanced company search ( with ratings)
- Markets page filters and historical industry data
- Get Edge Annual
Edge
-
$41.58 /month
billed annually - Full site access including KingsCrowd's qualitative analyst reports.
- Plan Includes:
- Everything in Edge, plus
- Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
- Search and filter based on Analyst Reports
- In-depth risk ratings for every raise
- Get Edge Pro Annual
Edge Pro
Already a member? Log in here.